A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab
Abstract
OBJECTIVE: To systematically review ocular and systemic events in treatment of wet age-related macular degeneration (AMD) with anti-vascular endothelial growth factor antibodies, ranibizumab and bevacizumab, and to provide a detailed perspective of their differences on clinical use, efficacy and safety. RESEARCH DESIGN AND METHODS: This review was based on a 2010 PubMed literature search performed using two separate terms: 'lucentis' OR 'ranibizumab' AND 'age-related macular degeneration' OR 'AMD' or 'avastin' OR 'bevacizumab' AND 'age-related macular degeneration' OR 'AMD'. A clinical diagnosis of wet AMD was defined by the authors of the trial reports. Clinical studies that met Level I or Level II evidence criteria were considered for review. FINDINGS: Eight large, randomized, controlled trials of ranibizumab (Level I) included 1,485 patients (range 162-716) and four open-label studies of ranibizumab (Level II) included 4,484 patients (range 32-4,300). Six studies (one Level I, five Level II) of bevacizumab included 424 patients (range 28-165). All demonstrated improvements in visual acuity. Only one study (Level II) compared the efficacy of ranibizumab and bevacizumab. Adverse ocular and systemic safety events occurring during the study were prospectively recorded for ranibizumab, irrespective of their suspected relationship to study treatments. Only three of six bevacizumab studies reported details of adverse ocular or systemic events. There was extensive Level I and Level II evidence to support both the efficacy and safety of ranibizumab in wet AMD. Data suggest that bevacizumab provides efficacy in wet AMD, but the safety profile of intravitreal bevacizumab remains to be established. CONCLUSION: In contrast to ranibizumab, current safety data for bevacizumab are incomplete and not yet robust. If the medical community remains committed to using intravitreal bevacizumab, it is critical to establish that it has an acceptable safety profile, supported by evidence-based medicine. Considerable further research is warranted to achieve this.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SLRs with single authors can be found in SE and other research areas.
“Despite its disadvantages, we can find SLRs with single authors in SE (Malhotra, 2015) and other research areas (Mitchell, 2011).”
From A software engineering perspective on engineering machine learning systems: State of the art and challenges (2021) · cites this paper as Mitchell, 2011
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886 · see citing works
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157 · see citing works
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., JAMPEL, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,794 · see citing works
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · see citing works
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · see citing works
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379 · see citing works
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318 · see citing works
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858 · see citing works
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · see citing works
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J. A., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. C. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 802 · see citing works
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683 · see citing works
Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts
Gehrs, K. M., Anderson, D. H., Johnson, L. V., & Hageman, G. S. (2006) · Annals of Medicine · doi:10.1080/07853890600946724 · Cited by 633 · see citing works
Kvanta, A., Algvere, P. V., Berglin, L., & Seregard, S. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70522-7 · Cited by 622 · see citing works
Fung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 535 · see citing works
Increased expression of angiogenic growth factors in age-related maculopathy
Kliffen, M., SHARMA, H. S., Mooy, C. M., KERKVLIET, S., & de Jong, P. T. V. M. (1997) · British Journal of Ophthalmology · doi:10.1136/bjo.81.2.154 · Cited by 501 · see citing works
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 447 · see citing works
Abraham, P., Yue, H., & Wilson, L. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.04.011 · Cited by 441 · see citing works
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Heier, J. S., Antoszyk, A. N., PAVAN, P. R., Leff, S. R., Rosenfeld, P. J., Ciulla, T. A., Dreyer, R. F., Gentile, R. C., Sy, J. P., Hantsbarger, G. L., et al. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.052 · Cited by 360 · see citing works
Boyer, D. S., Heier, J. S., Brown, D. M., Francom, S. F., Ianchulev, T., & Rubio, R. G. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.024 · Cited by 347 · see citing works
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304 · see citing works
Ranibizumab: Phase III clinical trial results.
Rosenfeld, P. J., Rich, R., & Lalwani, G. A. (2006) · PubMed · doi:10.1016/j.ohc.2006.05.009 · Cited by 299 · see citing works
Mitchell, P. L. R., Jf, K., Lanzetta, P., Holz, F. G., Prünte, C. F., Schmidt-Erfurth, U. M., Tano, Y., & Wolf, S. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.159160 · Cited by 297 · see citing works
Self-citation⁎ (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.064 · Cited by 291 · see citing works
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269 · see citing works
Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration
D’Amico, D. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.027 · Cited by 260 · see citing works
Chang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 239 · see citing works
Cardiovascular Risk Factors and the Long-term Incidence of Age-Related Macular Degeneration
Tan, J. S. L., Mitchell, P., Smith, W., & Wang, J. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.033 · Cited by 238 · see citing works
Self-citationBoyd, S. R. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.12.1644 · Cited by 230 · see citing works
Tufail, A., Patel, P. J., Egan, C. A., Hykin, P. G., da Cruz, L., Gregor, Z. J., Dowler, J. G. F., Majid, M. A., Bailey, C., Mohamed, Q. A., et al. (2010) · BMJ · doi:10.1136/bmj.c2459 · Cited by 213 · see citing works
Curtis, L. H. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.223 · Cited by 192 · see citing works
Antoszyk, A. N., Tuomi, L., Chung, C. Y., & Singh, A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.029 · Cited by 189 · see citing works
Rosenfeld, P. J., Heier, J. S., Hantsbarger, G. L., & Shams, N. K. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.027 · Cited by 189 · see citing works
Clinical update: new treatments for age-related macular degeneration
Wong, T. Y., Liew, G., & Mitchell, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61104-0 · Cited by 165 · see citing works
Self-citationBevacizumab for Neovascular Ocular Diseases
Lynch, S. S., & Cheng, C. M. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h316 · Cited by 157 · see citing works
Ranibizumab for Neovascular Age-Related Macular Degeneration
Liew, G., & Mitchell, P. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063011 · Cited by 156 · see citing works
Self-citationHIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMAB
Kahook, M. Y., Liu, L., Ruzycki, P. A., et al. (2010) · Retina · doi:10.1097/iae.0b013e3181d50cea · Cited by 132 · see citing works
Lazić, R., & Gabrić, N. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.006 · Cited by 127 · see citing works
Age-related macular degeneration and mortality from cardiovascular disease or stroke
Tan, J., Wang, J. J., Liew, G., Rochtchina, E., & Mitchell, P. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.131706 · Cited by 103 · see citing works
Self-citationImproved Vision-Related Function After Ranibizumab vs Photodynamic Therapy
Bressler, N. M. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2008.562 · Cited by 97 · see citing works
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data
Ross, J. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.394 · Cited by 81 · see citing works
Alexander, S. L., Linde‐Zwirble, W. T., Werther, W., Depperschmidt, E. E., Wilson, L., Palanki, R., Saroj, N., Butterworth, S. L., & Ianchulev, T. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.017 · Cited by 79 · see citing works
Bashshur, Z. F. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.10.1357 · Cited by 77 · see citing works
Subramanian, M. L., Ness, S. D., Abedi, G., Ahmed, E., Daly, M. K., Feinberg, E. B., Bhatia, S. P., Patel, P. M., Nguyen, M., & Houranieh, A. M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.07.009 · Cited by 72 · see citing works
Weigert, G., Michels, S., Sacu, S., Varga, A., Prager, F., Geitzenauer, W., & Schmidt-Erfurth, U. M. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.125823 · Cited by 69 · see citing works
Intravitreal Ranibizumab and Bevacizumab: A Review of Risk
Dafer, R. M., Schneck, M. J., Friberg, T. R., & Jay, W. M. (2007) · Seminars in Ophthalmology · doi:10.1080/08820530701543024 · Cited by 64 · see citing works
Tano, Y., & Ohji, M. (2010) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01843.x · Cited by 50 · see citing works
Clinical safety of ranibizumab in age-related macular degeneration
Schmidt-Erfurth, U. M. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903418422 · Cited by 50 · see citing works
Current and emerging therapies for the treatment of age-related macular degeneration
Lauer, A. K. (2008) · Clinical ophthalmology · doi:10.2147/opth.s1485 · Cited by 49 · see citing works
Sacu, S., Michels, S., Prager, F., Weigert, G., Dunavoelgyi, R., Geitzenauer, W., Prünte, C. F., & Schmidt-Erfurth, U. M. (2009) · Eye · doi:10.1038/eye.2008.423 · Cited by 45 · see citing works
Subretinal Bevacizumab Detection after Intravitreous Injection in Rabbits
Dib, E., Maia, M., Longo‐Maugéri, I. M., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1225 · Cited by 39 · see citing works
Potter, M. J., Claudio, C. C., & Szabo, S. M. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.155531 · Cited by 32 · see citing works
Hahn, R., Sacu, S., Michels, S., Varga, A., Weigert, G., Geitzenauer, W., Vécsei‐Marlovits, P. V., & Schmidt-Erfurth, U. M. (2007) · Der Ophthalmologe · doi:10.1007/s00347-007-1547-4 · Cited by 26 · see citing works
Systemic Adverse Events after Bevacizumab
Roth, D. B., King, A., Weiss, M., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.02.011 · Cited by 20 · see citing works
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration
Schmucker, C. M., Antes, G., & Lelgemann, M. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1249-5 · Cited by 14 · see citing works
Subramanian, M. L., Abedi, G., Ness, S. D., et al. (2010) · Investigative Ophthalmology & Visual Science · Cited by 3 · see citing works
Treatment of macular degeneration - controversy and hope
McGimpsey, S. J., & Gillies, M. C. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.125070 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748 · see citing works
Giray, G. (2021) · Journal of Systems and Software · doi:10.1016/j.jss.2021.111031 · Cited by 187 · see citing works
Aflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142 · see citing works
Holekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88 · see citing works
miRNAs as potential therapeutic targets for age-related macular degeneration
Wang, S., Koster, K. M., He, Y., & Zhou, Q. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.176 · Cited by 67 · see citing works
- Authors
- Mitchell, P.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Mitchell, Paul
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2011-05-31
- Volume
- 27
- Issue
- 7
- Pages
- 1465-1475
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2157848273
- Cited by
- 102
- References
- 57
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 15 · 2015: 7 · 2014: 17 · 2013: 9 · 2012: 13
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Allergan
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, anti-VEGF therapy, intravitreal injection, visual acuity outcomes, drug safety, adverse events, treatment efficacy comparison
- MeSH terms
- Bevacizumab, Ranibizumab, Algorithms, Antibodies, Monoclonal, Humans, Macular Degeneration, Neovascularization, Pathologic, Randomized Controlled Trials as Topic, Treatment Outcome, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
